Close
Close

Astellas Pharma Global Development, Inc. - Acute Myeloid Leukemia (AML)

Partner

Not provided

Rare Disease

Acute Myeloid Leukemia (AML)

Sponsor

Astellas Pharma Global Development, Inc.

Access Program Information

The purpose of this study is to provide expanded access to ASP2215 for subjects with FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in composite complete remission (CRc) (complete remission [CR], complete remission with incomplete hematologic recovery [CRi], complete remission with incomplete platelet recovery [CRp]) with MRD without access to comparable or alternative therapy.

Contact

Contact: Astellas Pharma Global Development (800-888-7704)

Locations
  • Canada
  • United States
  • Louisville, Kentucky, United States
  • United States
  • New Orleans, Louisiana, United States
  • United States
  • Baltimore, Maryland, United States
  • United States
  • Boston, Massachusetts, United States
  • United States
  • Saint Louis, Missouri, United States
  • United States
  • Albuquerque, New Mexico, United States
  • United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • United States
  • Morgantown, West Virginia, United States

Free Newsletter